Catherine Garcia, MD
Family Medicine · Orange, CANPI 1376679175
Payments from drug & device makers
Across 241 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$742
- Boehringer Ingelheim$416
- Lilly USA, LLC$361
- Pfizer$325
- Amgen$290
- GSK$289
- plus $3K from 29 others
What the payments were for
- Food & beverage$4,928100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 40 | $742 |
| Boehringer Ingelheim | 19 | $416 |
| Lilly USA, LLC | 17 | $361 |
| Pfizer | 17 | $325 |
| Amgen(2 entities) | 8 | $290 |
| GSK | 15 | $289 |
| Merck | 17 | $281 |
| AstraZeneca | 16 | $254 |
| AbbVie | 12 | $251 |
| Johnson & Johnson | 11 | $247 |
| Abbott | 7 | $177 |
| UCB, Inc. | 2 | $138 |
| Abiomed | 6 | $135 |
| Bayer | 7 | $126 |
| Novartis | 8 | $116 |
| Sanofi-aventis U.S. LLC | 5 | $97 |
| Dexcom, Inc. | 5 | $80 |
| Exact Sciences | 3 | $78 |
| Phathom Pharmaceuticals, Inc. | 3 | $62 |
| Exeltis, USA Inc. | 2 | $52 |
| Astellas Pharma US Inc | 3 | $48 |
| Amarin Pharma, Inc. | 2 | $45 |
| Teva Pharmaceuticals USA, Inc. | 2 | $45 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Boston Scientific | 2 | $33 |
| Hologic Sales And Service, LLC | 1 | $29 |
| Teleflex LLC | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Averitas Pharma Inc. | 1 | $23 |
| Gilead | 1 | $23 |
| Mayne Pharma Commercial LLC | 1 | $22 |
| Edwards Lifesciences | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,928 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 89 | $102,441 |
| JardianceEmpagliflozin | 68 | $64,863 |
| EliquisApixaban | 47 | $32,586 |
| JanuviaSitagliptin Phosphate | 21 | $24,133 |
| FarxigaDapagliflozin Propanediol | 20 | $18,817 |
| RybelsusSemaglutide | 20 | $18,103 |
| LinzessLinaclotide | 23 | $12,055 |
| MyrbetriqMirabegron | 12 | $8,612 |
| TradjentaLinagliptin | 13 | $6,489 |
| VascepaIcosapent Ethyl | 20 | $6,121 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,804 |
| Atorvastatin Calcium | 378 | $4,184 |
| Levothyroxine Sodium | 278 | $3,584 |
| Wixela InhubFluticasone Propion/Salmeterol | 16 | $3,031 |
| Ezetimibe-SimvastatinEzetimibe/Simvastatin | 25 | $2,832 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $742 | $120,545109 claims |
| Boehringer IngelheimJardiance, Tradjenta | $416 | $71,35181 claims |
| PfizerEliquis | $325 | $32,58647 claims |
| MerckJanuvia | $281 | $24,13321 claims |
| AstraZenecaFarxiga | $254 | $18,81720 claims |
| AbbVieLinzess, Synthroid | $251 | $14,22550 claims |
| Astellas Pharma US IncMyrbetriq | $48 | $8,61212 claims |
| GSKBreo Ellipta | $289 | $4,80412 claims |
| Sanofi-aventis U.S. LLCLantus | $97 | $1,11413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Orange
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.